SE538503C2 - New dextran sulfate - Google Patents
New dextran sulfate Download PDFInfo
- Publication number
- SE538503C2 SE538503C2 SE1451349A SE1451349A SE538503C2 SE 538503 C2 SE538503 C2 SE 538503C2 SE 1451349 A SE1451349 A SE 1451349A SE 1451349 A SE1451349 A SE 1451349A SE 538503 C2 SE538503 C2 SE 538503C2
- Authority
- SE
- Sweden
- Prior art keywords
- dextran sulfate
- dextran
- interval
- average
- sulfate
- Prior art date
Links
- 229960000633 dextran sulfate Drugs 0.000 title claims description 210
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims description 59
- 230000019635 sulfation Effects 0.000 claims description 54
- 238000005670 sulfation reaction Methods 0.000 claims description 54
- 238000005481 NMR spectroscopy Methods 0.000 claims description 44
- 150000003839 salts Chemical class 0.000 claims description 30
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 27
- 150000002500 ions Chemical class 0.000 claims description 7
- 159000000000 sodium salts Chemical class 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 2
- 238000004611 spectroscopical analysis Methods 0.000 claims description 2
- 229920002307 Dextran Polymers 0.000 description 43
- 229960002086 dextran Drugs 0.000 description 43
- 241001465754 Metazoa Species 0.000 description 30
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 27
- 239000000126 substance Substances 0.000 description 26
- 238000000034 method Methods 0.000 description 21
- 241000700159 Rattus Species 0.000 description 15
- 201000002491 encephalomyelitis Diseases 0.000 description 15
- 230000004071 biological effect Effects 0.000 description 14
- 230000000694 effects Effects 0.000 description 12
- 239000000523 sample Substances 0.000 description 12
- 238000001228 spectrum Methods 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 11
- 238000002347 injection Methods 0.000 description 11
- 239000007924 injection Substances 0.000 description 11
- 239000000203 mixture Substances 0.000 description 11
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 11
- 239000007858 starting material Substances 0.000 description 11
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 10
- 201000010099 disease Diseases 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 238000000149 argon plasma sintering Methods 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 238000011282 treatment Methods 0.000 description 9
- 230000037396 body weight Effects 0.000 description 8
- 238000012512 characterization method Methods 0.000 description 8
- 238000000990 heteronuclear single quantum coherence spectrum Methods 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 8
- 238000001556 precipitation Methods 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 238000001542 size-exclusion chromatography Methods 0.000 description 8
- 238000007920 subcutaneous administration Methods 0.000 description 8
- 230000001186 cumulative effect Effects 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 7
- 238000005227 gel permeation chromatography Methods 0.000 description 7
- 238000011081 inoculation Methods 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 6
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 description 6
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 6
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 229910052799 carbon Inorganic materials 0.000 description 6
- 238000009826 distribution Methods 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- YASYEJJMZJALEJ-UHFFFAOYSA-N Citric acid monohydrate Chemical compound O.OC(=O)CC(O)(C(O)=O)CC(O)=O YASYEJJMZJALEJ-UHFFFAOYSA-N 0.000 description 5
- 239000012267 brine Substances 0.000 description 5
- 229960002303 citric acid monohydrate Drugs 0.000 description 5
- 238000001816 cooling Methods 0.000 description 5
- 238000010253 intravenous injection Methods 0.000 description 5
- 229960001412 pentobarbital Drugs 0.000 description 5
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 5
- 231100000419 toxicity Toxicity 0.000 description 5
- 230000001988 toxicity Effects 0.000 description 5
- -1 0.9 % NaCI saline Chemical compound 0.000 description 4
- 208000000059 Dyspnea Diseases 0.000 description 4
- 206010013975 Dyspnoeas Diseases 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 238000005570 heteronuclear single quantum coherence Methods 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 230000001483 mobilizing effect Effects 0.000 description 4
- 210000005259 peripheral blood Anatomy 0.000 description 4
- 239000011886 peripheral blood Substances 0.000 description 4
- 239000008363 phosphate buffer Substances 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- AKEJUJNQAAGONA-UHFFFAOYSA-N sulfur trioxide Chemical compound O=S(=O)=O AKEJUJNQAAGONA-UHFFFAOYSA-N 0.000 description 4
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- KEQGZUUPPQEDPF-UHFFFAOYSA-N 1,3-dichloro-5,5-dimethylimidazolidine-2,4-dione Chemical compound CC1(C)N(Cl)C(=O)N(Cl)C1=O KEQGZUUPPQEDPF-UHFFFAOYSA-N 0.000 description 3
- FZWBNHMXJMCXLU-UHFFFAOYSA-N 2,3,4,5-tetrahydroxy-6-[3,4,5-trihydroxy-6-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxyhexanal Chemical compound OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OCC(O)C(O)C(O)C(O)C=O)O1 FZWBNHMXJMCXLU-UHFFFAOYSA-N 0.000 description 3
- 238000005084 2D-nuclear magnetic resonance Methods 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 238000000692 Student's t-test Methods 0.000 description 3
- 208000002552 acute disseminated encephalomyelitis Diseases 0.000 description 3
- 230000037005 anaesthesia Effects 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- XTHPWXDJESJLNJ-UHFFFAOYSA-N chlorosulfonic acid Substances OS(Cl)(=O)=O XTHPWXDJESJLNJ-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000010354 integration Effects 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 231100000053 low toxicity Toxicity 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 201000006417 multiple sclerosis Diseases 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- VWDWKYIASSYTQR-UHFFFAOYSA-N sodium nitrate Chemical compound [Na+].[O-][N+]([O-])=O VWDWKYIASSYTQR-UHFFFAOYSA-N 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- FTOAOBMCPZCFFF-UHFFFAOYSA-N 5,5-diethylbarbituric acid Chemical compound CCC1(CC)C(=O)NC(=O)NC1=O FTOAOBMCPZCFFF-UHFFFAOYSA-N 0.000 description 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- 208000016192 Demyelinating disease Diseases 0.000 description 2
- 229920001503 Glucan Polymers 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 2
- 238000012565 NMR experiment Methods 0.000 description 2
- 238000011887 Necropsy Methods 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 239000008366 buffered solution Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000007385 chemical modification Methods 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000000498 cooling water Substances 0.000 description 2
- 238000005100 correlation spectroscopy Methods 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 238000005886 esterification reaction Methods 0.000 description 2
- 230000003862 health status Effects 0.000 description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 239000002054 inoculum Substances 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 229960002725 isoflurane Drugs 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 238000004811 liquid chromatography Methods 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000004062 sedimentation Methods 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 230000003595 spectral effect Effects 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 238000001370 static light scattering Methods 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 230000001180 sulfating effect Effects 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 208000030090 Acute Disease Diseases 0.000 description 1
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 206010011906 Death Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010019468 Hemiplegia Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 206010061924 Pulmonary toxicity Diseases 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 229960002319 barbital Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 238000012754 cardiac puncture Methods 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 229940041984 dextran 1 Drugs 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 208000012997 experimental autoimmune encephalomyelitis Diseases 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 150000002303 glucose derivatives Chemical class 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 238000004340 gradient COSY Methods 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 229920006158 high molecular weight polymer Polymers 0.000 description 1
- 201000008298 histiocytosis Diseases 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 238000000569 multi-angle light scattering Methods 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 238000005016 nuclear Overhauser enhanced spectroscopy Methods 0.000 description 1
- 238000000238 one-dimensional nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 231100000374 pneumotoxicity Toxicity 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000028527 righting reflex Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000003998 size exclusion chromatography high performance liquid chromatography Methods 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 1
- 239000004317 sodium nitrate Substances 0.000 description 1
- 235000010344 sodium nitrate Nutrition 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- YALHCTUQSQRCSX-UHFFFAOYSA-N sulfane sulfuric acid Chemical compound S.OS(O)(=O)=O YALHCTUQSQRCSX-UHFFFAOYSA-N 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 238000011191 terminal modification Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 238000002495 two-dimensional nuclear magnetic resonance spectrum Methods 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
- C08B37/0021—Dextran, i.e. (alpha-1,4)-D-glucan; Derivatives thereof, e.g. Sephadex, i.e. crosslinked dextran
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/721—Dextrans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
- C08L5/02—Dextran; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L2203/00—Applications
- C08L2203/02—Applications for biomedical use
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Polymers & Plastics (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Materials Engineering (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (31)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE1451349A SE538503C2 (sv) | 2014-11-11 | 2014-11-11 | New dextran sulfate |
| TR2019/00334T TR201900334T4 (tr) | 2014-11-11 | 2015-11-10 | Yeni Dekstran Sülfat |
| RS20190040A RS58222B1 (sr) | 2014-11-11 | 2015-11-10 | Novi dekstran sulfat |
| LTEP15858497.9T LT3217988T (lt) | 2014-11-11 | 2015-11-10 | Naujasis dekstrano sulfatas |
| US15/525,818 US10407514B2 (en) | 2014-11-11 | 2015-11-10 | Dextran sulfate |
| DK15858497.9T DK3217988T3 (en) | 2014-11-11 | 2015-11-10 | HOW TO UNKNOWN DEXTRANSULPHATE |
| SM20190032T SMT201900032T1 (it) | 2014-11-11 | 2015-11-10 | Nuovo solfato di destrano |
| MX2017006122A MX364314B (es) | 2014-11-11 | 2015-11-10 | Nuevo sulfato de dextrano. |
| ES15858497T ES2706287T3 (es) | 2014-11-11 | 2015-11-10 | Sulfato de dextrano nuevo |
| CN201580061059.4A CN107106595B (zh) | 2014-11-11 | 2015-11-10 | 新型硫酸葡聚糖 |
| MYPI2017701627A MY181598A (en) | 2014-11-11 | 2015-11-10 | New dextran sulfate |
| JP2017525349A JP6251459B1 (ja) | 2014-11-11 | 2015-11-10 | 新規なデキストラン硫酸 |
| PT15858497T PT3217988T (pt) | 2014-11-11 | 2015-11-10 | Novo sulfato de dextrano |
| HUE15858497A HUE042806T2 (hu) | 2014-11-11 | 2015-11-10 | Új dextrán-szulfát |
| BR112017009752-4A BR112017009752B1 (pt) | 2014-11-11 | 2015-11-10 | Sulfato de dextrano |
| EP15858497.9A EP3217988B1 (en) | 2014-11-11 | 2015-11-10 | New dextran sulfate |
| PL15858497T PL3217988T3 (pl) | 2014-11-11 | 2015-11-10 | Nowy siarczan dekstranu |
| NZ731141A NZ731141A (en) | 2014-11-11 | 2015-11-10 | New dextran sulfate |
| SG11201703198PA SG11201703198PA (en) | 2014-11-11 | 2015-11-10 | New dextran sulfate |
| EA201790856A EA032383B1 (ru) | 2014-11-11 | 2015-11-10 | Новый сульфат декстрана |
| SI201530562T SI3217988T1 (sl) | 2014-11-11 | 2015-11-10 | Novi dekstran sulfat |
| PCT/SE2015/051188 WO2016076780A1 (en) | 2014-11-11 | 2015-11-10 | New dextran sulfate |
| KR1020177013121A KR101834710B1 (ko) | 2014-11-11 | 2015-11-10 | 신규한 덱스트란 설페이트 |
| HRP20190073TT HRP20190073T1 (hr) | 2014-11-11 | 2015-11-10 | Novi dekstran sulfat |
| AU2015347361A AU2015347361B2 (en) | 2014-11-11 | 2015-11-10 | New dextran sulfate |
| CA2967264A CA2967264C (en) | 2014-11-11 | 2015-11-10 | New dextran sulfate |
| IL251871A IL251871A (en) | 2014-11-11 | 2017-04-23 | Dextran sulfate has enhanced biological properties |
| PH12017500799A PH12017500799B1 (en) | 2014-11-11 | 2017-04-27 | New dextran sulfate |
| SA517381478A SA517381478B1 (ar) | 2014-11-11 | 2017-05-07 | كبريتات ديكستران لها تأثيرات بيولوجية محسنة |
| CY20191100024T CY1121336T1 (el) | 2014-11-11 | 2019-01-10 | Νεα θειικη δεξτρανη |
| US16/520,930 US10730960B2 (en) | 2014-11-11 | 2019-07-24 | Dextran sulfate |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE1451349A SE538503C2 (sv) | 2014-11-11 | 2014-11-11 | New dextran sulfate |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| SE1451349A1 SE1451349A1 (sv) | 2016-05-12 |
| SE538503C2 true SE538503C2 (sv) | 2016-08-16 |
Family
ID=55954726
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SE1451349A SE538503C2 (sv) | 2014-11-11 | 2014-11-11 | New dextran sulfate |
Country Status (30)
| Country | Link |
|---|---|
| US (2) | US10407514B2 (sv) |
| EP (1) | EP3217988B1 (sv) |
| JP (1) | JP6251459B1 (sv) |
| KR (1) | KR101834710B1 (sv) |
| CN (1) | CN107106595B (sv) |
| AU (1) | AU2015347361B2 (sv) |
| BR (1) | BR112017009752B1 (sv) |
| CA (1) | CA2967264C (sv) |
| CY (1) | CY1121336T1 (sv) |
| DK (1) | DK3217988T3 (sv) |
| EA (1) | EA032383B1 (sv) |
| ES (1) | ES2706287T3 (sv) |
| HR (1) | HRP20190073T1 (sv) |
| HU (1) | HUE042806T2 (sv) |
| IL (1) | IL251871A (sv) |
| LT (1) | LT3217988T (sv) |
| MX (1) | MX364314B (sv) |
| MY (1) | MY181598A (sv) |
| NZ (1) | NZ731141A (sv) |
| PH (1) | PH12017500799B1 (sv) |
| PL (1) | PL3217988T3 (sv) |
| PT (1) | PT3217988T (sv) |
| RS (1) | RS58222B1 (sv) |
| SA (1) | SA517381478B1 (sv) |
| SE (1) | SE538503C2 (sv) |
| SG (1) | SG11201703198PA (sv) |
| SI (1) | SI3217988T1 (sv) |
| SM (1) | SMT201900032T1 (sv) |
| TR (1) | TR201900334T4 (sv) |
| WO (1) | WO2016076780A1 (sv) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2777836T3 (es) * | 2017-05-17 | 2020-08-06 | Tx Medic Ab | Tratamiento del glaucoma |
| WO2018212708A1 (en) | 2017-05-17 | 2018-11-22 | Tx Medic Ab | Treatment of glaucoma |
| IL272935B2 (en) * | 2017-09-08 | 2025-04-01 | Tx Medic Ab | New use of dextran sulfate |
| JP7576263B2 (ja) * | 2018-06-20 | 2024-10-31 | デュポン・インダストリアル・バイオサイエンシーズ・ユーエスエイ・エルエルシー | 多糖誘導体及び同一物を含む組成物 |
| SE543275C2 (sv) * | 2019-03-07 | 2020-11-10 | Tx Medic Ab | Treatment efficiency evaluation |
| SE544015C2 (en) * | 2019-06-18 | 2021-11-02 | Tx Medic Ab | Allogenic car-t cell therapy |
| CN115461060A (zh) * | 2020-04-15 | 2022-12-09 | Tx医生公司 | 冠状病毒感染的治疗 |
| GB202008919D0 (en) | 2020-06-11 | 2020-07-29 | Univ Birmingham | Polysaccharide conpositions and therapeutic gels |
| SE544447C2 (en) * | 2020-09-29 | 2022-05-31 | Tx Medic Ab | Treatment of fatty liver diseases |
| US20240082296A1 (en) | 2020-10-09 | 2024-03-14 | Tx Medic Ab | Treatment of muscle atrophy using dextran sulfate |
| US20240189343A1 (en) * | 2021-04-14 | 2024-06-13 | Tx Medic Ab | Treatment of virus infections |
| CN117157084A (zh) * | 2021-10-14 | 2023-12-01 | Tx医生公司 | 病毒感染的治疗 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3141014A (en) * | 1960-03-31 | 1964-07-14 | Meito Sangyo Kk | Sodium and potassium salts of the dextran sulphuric acid ester having substantially no anticoagulant activity but having lipolytic activity and the method of preparation thereof |
| JPS4730167Y1 (sv) | 1967-03-09 | 1972-09-09 | ||
| JPS469570Y1 (sv) | 1968-08-28 | 1971-04-05 | ||
| US4232150A (en) | 1979-07-09 | 1980-11-04 | American Cyanamid Company | Oligosaccharide precursors to substituted O-α-D and O-β-D-multigalactopyranosyl and glucopyranosyl 1→4 and 1→6 galactopyranosyl 1→6α-D-glucopyranoses |
| US4221907A (en) * | 1979-07-09 | 1980-09-09 | American Cyanamid Company | Substituted O-α-D and O-β-D-multi-galactopyranosyl and glucopyranosyl 1→4 and 1→6 galactopyranosyl 1→6 α-D-glucopyranoses |
| US4855416A (en) * | 1983-07-25 | 1989-08-08 | Polydex Pharmaceuticals, Ltd | Method for the manufacture of dextran sulfate and salts thereof |
| EP0240098A3 (en) | 1986-04-04 | 1989-05-10 | Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo | Oligo and polysaccharides for the treatment of diseases caused by retroviruses |
| IL79254A0 (en) | 1986-06-26 | 1986-09-30 | Hadassah Med Org | Compositions for preventing graft rejection |
| IL88554A0 (en) | 1988-12-01 | 1989-07-31 | Hadassah Med Org | Compositions containing a compound binding to a heparin receptor |
| TW318142B (sv) | 1991-06-03 | 1997-10-21 | Mitsubishi Chemicals Co Ltd | |
| US5464815A (en) | 1993-09-08 | 1995-11-07 | Genentech, Inc. | Inhibition of heparin-binding |
| JPH08301771A (ja) | 1995-03-08 | 1996-11-19 | Shiseido Co Ltd | 腎疾患の予防または治療用製剤 |
| AUPN261895A0 (en) * | 1995-04-28 | 1995-05-18 | Australian National University, The | Preparation and use of sulfated oligosaccharides |
| FR2772382B1 (fr) | 1997-12-11 | 2000-03-03 | Solutions | Derives de dextrane, leur procede de preparation et leurs applications comme medicaments a action biologique specifique |
| JP2000178196A (ja) * | 1998-12-11 | 2000-06-27 | Seikagaku Kogyo Co Ltd | 新規ヒアルロニダーゼ阻害剤及び外用剤 |
| CN1347919A (zh) | 2000-10-12 | 2002-05-08 | 中国科学院生态环境研究中心 | 带有支链的硫酸酯化寡糖的制备 |
| FR2832708B1 (fr) | 2001-11-29 | 2004-02-13 | Organes Tissus Regeneration Re | Procede de sulfonation de composes comprenant des groupements hydroxyle (oh) libres ou des amines primaires ou secondaires |
| US20040009953A1 (en) * | 2002-01-10 | 2004-01-15 | Comper Wayne D. | Antimicrobial charged polymers that exhibit resistance to lysosomal degradation during kidney filtration and renal passage, compositions and method of use thereof |
| SE525461C3 (sv) | 2002-11-28 | 2005-03-23 | Prophymed Ab | Ny användning av dextransulfat |
| WO2008153962A2 (en) | 2007-06-08 | 2008-12-18 | The Trustees Of The University Of Pennylvania | Method of reducing tissue loss in pancreatic islet cell transplantation |
| US8993536B2 (en) | 2009-02-02 | 2015-03-31 | Otsuka Chemical Co., Ltd. | Low-molecular polysulfated hyaluronic acid derivative and medicine containing same |
| SE537742C2 (sv) | 2013-05-13 | 2015-10-13 | Tx Medic Ab | Dextransulfat för cellmobilisering |
| CN103554297B (zh) * | 2013-10-21 | 2016-09-07 | 兰州大学 | 一种高硫代度红芪多糖硫酸酯的制备方法及其应用 |
| PT3154551T (pt) * | 2014-06-12 | 2019-01-18 | Tx Medic Ab | A utilização de sulfato de dextrano tendo uma massa molecular média inferior a 10000 da para induzir angiogénese num sujeito |
-
2014
- 2014-11-11 SE SE1451349A patent/SE538503C2/sv not_active IP Right Cessation
-
2015
- 2015-11-10 CN CN201580061059.4A patent/CN107106595B/zh active Active
- 2015-11-10 EP EP15858497.9A patent/EP3217988B1/en active Active
- 2015-11-10 PT PT15858497T patent/PT3217988T/pt unknown
- 2015-11-10 WO PCT/SE2015/051188 patent/WO2016076780A1/en not_active Ceased
- 2015-11-10 PL PL15858497T patent/PL3217988T3/pl unknown
- 2015-11-10 AU AU2015347361A patent/AU2015347361B2/en active Active
- 2015-11-10 ES ES15858497T patent/ES2706287T3/es active Active
- 2015-11-10 HR HRP20190073TT patent/HRP20190073T1/hr unknown
- 2015-11-10 TR TR2019/00334T patent/TR201900334T4/tr unknown
- 2015-11-10 CA CA2967264A patent/CA2967264C/en active Active
- 2015-11-10 SG SG11201703198PA patent/SG11201703198PA/en unknown
- 2015-11-10 US US15/525,818 patent/US10407514B2/en active Active
- 2015-11-10 MY MYPI2017701627A patent/MY181598A/en unknown
- 2015-11-10 HU HUE15858497A patent/HUE042806T2/hu unknown
- 2015-11-10 LT LTEP15858497.9T patent/LT3217988T/lt unknown
- 2015-11-10 BR BR112017009752-4A patent/BR112017009752B1/pt active IP Right Grant
- 2015-11-10 DK DK15858497.9T patent/DK3217988T3/en active
- 2015-11-10 SI SI201530562T patent/SI3217988T1/sl unknown
- 2015-11-10 MX MX2017006122A patent/MX364314B/es active IP Right Grant
- 2015-11-10 SM SM20190032T patent/SMT201900032T1/it unknown
- 2015-11-10 EA EA201790856A patent/EA032383B1/ru not_active IP Right Cessation
- 2015-11-10 KR KR1020177013121A patent/KR101834710B1/ko active Active
- 2015-11-10 JP JP2017525349A patent/JP6251459B1/ja active Active
- 2015-11-10 NZ NZ731141A patent/NZ731141A/en unknown
- 2015-11-10 RS RS20190040A patent/RS58222B1/sr unknown
-
2017
- 2017-04-23 IL IL251871A patent/IL251871A/en active IP Right Grant
- 2017-04-27 PH PH12017500799A patent/PH12017500799B1/en unknown
- 2017-05-07 SA SA517381478A patent/SA517381478B1/ar unknown
-
2019
- 2019-01-10 CY CY20191100024T patent/CY1121336T1/el unknown
- 2019-07-24 US US16/520,930 patent/US10730960B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10730960B2 (en) | Dextran sulfate | |
| DK173818B1 (da) | Heparinderivat | |
| Pomin et al. | Residual keratan sulfate in chondroitin sulfate formulations for oral administration | |
| Santos et al. | Structural and functional analyses of bovine and porcine intestinal heparins confirm they are different drugs | |
| Tovar et al. | Structural and haemostatic features of pharmaceutical heparins from different animal sources: challenges to define thresholds separating distinct drugs | |
| UA127034C2 (uk) | Композиція мануронової дикарбонової кислоти | |
| JP2019056717A (ja) | 高純度ヘパリンおよびその製造方法 | |
| Li et al. | Antioxidant, anticoagulant and thrombolytic properties of SIP-IV, a sulfated polysaccharide from Sepia esculenta ink, and its derivatives | |
| Amaral et al. | End-on PEGylation of heparin: Effect on anticoagulant activity and complexation with protamine | |
| Liu et al. | Comparison of two kinds of Agrocybe cylindracea polysaccharides: Structural characteristic and antitumor activity | |
| JPS6322801A (ja) | Ｅｄｔａ不含のヘパリン、ヘパリン分画ならびに断片、それらの製造法及びそれらを含有する医薬品組成物 | |
| JP4585072B2 (ja) | ヘパリン解重合法、解重合ヘパリン、その誘導体および医薬組成物 | |
| DE69413467T2 (de) | Polyglucuronsäure als remittierendes Mittel für das nephrotische Syndrom und Symptome von Hepatopathie | |
| CN102247401A (zh) | 低分子量糖基化硫酸软骨素及其在抗hiv-1药物制备中的用途 | |
| CN114656577A (zh) | 一种通过抑制氧化应激发挥防治脑卒中效果的中性均一枸杞多糖 | |
| HK1236399A1 (en) | New dextran sulfate | |
| HK1236399B (en) | New dextran sulfate | |
| CN101502532A (zh) | 竹荪三螺旋多糖的应用 | |
| Sun et al. | PEGylated inulin as long-circulating pharmaceutical carrier | |
| AU2015203727B2 (en) | High Purity Heparin and Production Method Therefor | |
| CN120795196A (zh) | 一种用于肺部靶向的红花多糖及其制备方法和应用 | |
| CN119954985A (zh) | 化学修饰的糖胺聚糖及其制备方法和用途 | |
| HK40050737B (en) | High-molecular-weight fucans for treating fibrous adhesions and other diseases and conditions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| NUG | Patent has lapsed |